Previous 10 | Next 10 |
Organon & Co. (OGN) Q4 2021 Results Conference Call February 17, 2022 08:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Jason Gerberry - Bank of America Chris Schott - JP Morgan Greg Fraser - Truist Securities Umer Raf...
The following slide deck was published by Organon & Co. in conjunction with their 2022 Q4 earnings call. For further details see: Organon & Co. 2022 Q4 - Results - Earnings Call Presentation
Organon (NYSE:OGN) set its 2022 revenue in line with Wall Street forecasts even as the contraction in its topline and the bottom line continued for another quarter in Q4 2021. The revenue for the quarter dropped ~1% YoY to $1.6B as Established Brands generated $1.0B in revenue with a ~2% YoY ...
Organon press release (NYSE:OGN): Q4 Non-GAAP EPS of $1.37 beats by $0.10. Revenue of $1.6B (-0.6% Y/Y) beats by $20M. FY22 Guidance: Revenue of $6.1-$6.4B vs. $6.34B consensus. Adj. gross margin of mid 60%. SG&A as % of sales mid 20% R&D as % of sales mid to upper single digit. Adjus...
Nexplanon ® (etonogestrel implant), fertility, biosimilars grew double digits for full year Full year 2021 revenue of $6.3 billion Income from continuing operations before tax of $1.5 billion for full year 2021 Full year Adjusted EBITDA of $2.4 billion...
Organon (NYSE:OGN) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open. The consensus EPS Estimate is $1.27 and the consensus Revenue Estimate is $1.58B. Over the last 3 months, EPS estimates have seen 2 upward revisions and 3 downward. Revenue estimate...
Organon (NYSE:OGN) announced on Wednesday that the company acquired the rights for Marvelon and Mercilon combined oral hormonal daily contraceptive pills in China (including Hong Kong and Macau) from German pharma giant Bayer (OTCPK:BAYZF) (OTCPK:BAYRY). The company has also agreed to acquire...
Acquisition Immediately Adds to Organon’s Suite of Contraceptive Offerings and Continues to Build on Strong Foundation in Women’s Health Around the World Organon (NYSE: OGN) today announced that it has acquired the rights from Bayer AG to Marvelon ® an...
Last year proved to be a record-breaking year for IPOs, amid government stimulus and soaring valuations. However, this year, the market is under pressure because of the looming interest rate hikes. Though the market could remain under pressure in the upcoming months, Wall Street analysts expe...
Organon Canada Declares Paid Time Off for All Employees on International Women's Day; All Employees in Canada to Focus on Their Own Health in Recognition of Growing Women's Health Inequity Canada NewsWire As the COVID-19 pandemic continues to have a disproportionate ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...